Author: admin

  • Different Neanderthal clans had their signature dishes, among them rotten meat with maggots | Science

    Different Neanderthal clans had their signature dishes, among them rotten meat with maggots | Science

    Outside, the wind is icy and the temperature hovers around zero degrees, but inside the cave, a group of Neanderthals huddles around a fire. On flat stones, adults, children, and even an elderly person wait for a piece of gazelle they managed to hunt that morning to finish cooking. There are no pots or spoons, but there is technique. The piece of meat was dismembered following a specific cutting pattern, using something similar to a knife made from a sharpened piece of flint. For those who are still hungry, there are also seeds, remains of a tuber, and, of course, the house specialty: rotting meat teeming with nutritious larvae and maggots.

    This scene could have taken place 300,000 years ago somewhere between what is now central and western Europe. But unraveling with certainty how the Neanderthal communities that inhabited the region lived and, above all, what they ate is a titanic and painstaking task. However, little by little and thanks to scientific work, information is beginning to become increasingly conclusive. A pair of recently published studies elaborate on the idea that, while we cannot speak of gastronomy among Neanderthals, we can say that certain cultural practices existed around food.

    One of these studies, published last Friday in the journal Science Advances, proposes that worm consumption was the secret ingredient responsible for the extremely high nitrogen levels found in Neanderthal bones. For decades, analyses of bone remains from this species have shown exceptionally high levels of stable nitrogen isotopes, often higher than those of carnivorous animals such as wolves, hyenas, or lions. This has been interpreted to mean that Neanderthals were hypercarnivorous humans, occupying the highest level of the food chain. However, this hypothesis has been challenged. Human metabolism does not allow for the consumption of high amounts of protein, as specialized carnivores do. Therefore, a paradox arises: could Neanderthals show isotopic signatures typical of extreme carnivores if their physiology did not allow it?

    “There are elements that could explain many things about the lives of Neanderthals that we don’t usually consider because they’re not part of our food imagination, but they must be taken into account,” says Ainara Sistiaga, a researcher at the University of Copenhagen who did not participate in the study. This includes, for example, eating rotten meat, full of maggots. Something that today, except in some specific cultures like the Inuit (who eat seal meat fermented underground), is unthinkable and dangerous.

    This research suggests that Neanderthals’ signature dish was rotting meat infested with fly larvae, which are responsible for the extremely high nitrogen levels discovered at various sites throughout history. The authors’ explanation is as follows: the larvae, feeding on rotting meat, have even higher nitrogen levels than the meat itself, and when consumed along with the tissues, they significantly alter the isotopic record of the person who ingested them — in this case, the Neanderthals. It is also believed that this was a deliberate and strategic decision to increase the consumption of fats and proteins, especially during the colder months.

    The study has its limitations. Manuel Domínguez-Rodrigo, a professor at the University of Alcalá, Spain, points out that the hypothesis posed by the new research is “highly speculative.” For the academic, the high presence of nitrogen in prehistoric populations “could be the result of many different processes.” He gives as an example the fact that if Neanderthals had consumed large amounts of manure, they would have had the same level of nitrogen in their bones. “The problem is how to move from a speculative idea, such as the one presented in this article, to a scientifically verifiable proposition,” he summarizes. Until this happens, the expert asserts that the extremely high meat consumption among these humans continues to be more heuristic than “unproven alternative scenarios.”

    These uncertainties surrounding what really happened “demonstrate the complexity of reconstructing the diet of an extinct species that survived for thousands and thousands of years in climatic and geographic contexts so changing that we can’t even understand them today,” says Sistiaga. These types of studies, the expert points out, “contribute new pieces to the puzzle of human evolution.”

    From generation to generation

    Another piece of research comes from a study published on June 17 in the journal Frontiers in Environmental Archaeology. The authors compared the differences in the way two Neanderthal lineages that lived in nearby caves in the Levant (Near East) butchered animals they intended to eat.

    Anaëlle Jallon, a researcher at the Hebrew University of Jerusalem and co-author of the study, explains that “finding differences between these two sites indicates that there was a certain cultural diversity surrounding food among contemporary Neanderthal groups.” These communities used the caves for the same purposes: residential sections with areas dedicated to daily activities such as flint knapping, cooking, and garbage disposal, as well as for the burial of the deceased. Furthermore, both were surrounded by Mediterranean vegetation with the same animal species, and were occupied primarily during the winter.

    “For these reasons,” Jallon ventures, “we might expect that, if all Neanderthal groups behaved the same way, we would recover the same animal butchering techniques at these sites.” However, scientists now know that this was not the case and that each community had its own method of processing food. They also discovered that the differences persisted over time, indicating that the knowledge or traditions underlying these variations endured and were passed down from generation to generation.

    While the available evidence is insufficient to accurately reconstruct specific food preparation techniques, the researchers suggest that there were likely differences in tastes and cooking skills. “We can imagine that different Neanderthal groups used similar ingredients, but each had their own signature dishes, or that they cooked similar dishes, albeit following different recipes,” the author emphasizes.

    A food atlas

    Defining the Neanderthal diet is almost as difficult as trying to define a single human diet. Today, people in the Mediterranean don’t eat the same way people do in Southeast Asia. The same is true of our cousins. They occupied such a vast territory that compiling their food atlas is a risky undertaking. Furthermore, some foods, like meat, leave their mark, in this case on the bones. But others, like legumes or vegetables, don’t.

    Sistiaga goes into detail: “Plant remains, for example, are difficult to find in bones. Techniques such as dental tartar analysis have been used to detect plant DNA or proteins, but the findings are anecdotal.” The plant fibers found in the teeth of different individuals could have gotten there in many ways, not just through ingestion. “Plant remains are less well preserved in archaeological sites, so we still have an overrepresentation of animal proteins.” Hence the myth of hypercarnivores.

    But there was much more. A study published in 2023 found that 90,000 years ago, in what is now Lisbon, Portugal, Neanderthals feasted on charred seafood. Further into the central Iberian Peninsula, a 2017 study found that these early humans gathered and ate mushrooms. A 2011 review even suggests that honey may have been an important source of energy back then.

    What is beyond doubt is that the race for good food decisively shaped the genus Homo. A 2015 study suggested that the germ of the ability to cook appeared more than six million years ago. And that since then, the taste for cooked food has helped the human brain achieve its modern size and power, since once cooked, food becomes easier to digest and, in the same quantities as raw food, leaves more calories in the body.

    Evidence suggests that flavor optimization may have been one of the major evolutionary drivers. And it all began, perhaps, with a piece of maggot-infested meat.

    Sign up for our weekly newsletter to get more English-language news coverage from EL PAÍS USA Edition

    Continue Reading

  • Now everyone can stream their own games in the Xbox PC app.

    Now everyone can stream their own games in the Xbox PC app.

    Now everyone can stream their own games in the Xbox PC app.

    Image: Xbox

    Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.


    Continue Reading

  • FDA Expedites Durvalumab Review for Resectable Early-Stage Gastric, Gastroesophageal Cancers

    FDA Expedites Durvalumab Review for Resectable Early-Stage Gastric, Gastroesophageal Cancers

    The FDA has accepted the supplemental biologics license application (sBLA) for durvalumab (Imfinzi; AstraZeneca) to treat patients with resectable, early-stage, and locally advanced—stages II, III, or IVA—gastric and gastroesophageal (G/GEJ) cancers, granting the agent priority review status and breakthrough therapy designation, according to a news release from AstraZeneca.1

    Gastric cancers have a high rate of recurrence, necessitating novel treatment options. | Image Credit: © Gromik – stock.adobe.com

    These FDA actions are based on positive data observed in the phase 3, multinational, double-blind, randomized MATTERHORN trial, the results of which were presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine. In combination with a chemotherapy regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel; [FLOT]), durvalumab elicited meaningful improvements in event-free survival (EFS), the study’s primary end point, compared with FLOT alone.1,2

    “This priority review reinforces the potential for a perioperative approach with [durvalumab] to transform care for patients with early gastric and gastroesophageal junction cancers, who frequently face disease recurrence or progression even after curative-intent surgery and perioperative chemotherapy,” Susan Galbraith, executive vice president of oncology hematology research and development at AstraZeneca, said in the news release. “This novel treatment is the only immunotherapy-based regimen to show a statistically significant reduction in the risk of progression, recurrence, or death in this setting, and if approved, is poised to change the clinical paradigm.”1

    Detailed Results from the MATTERHORN Trial

    MATTERHORN investigators sought to evaluate the impact of adding durvalumab to the standard-of-care FLOT regimen for resectable G/GEJ cancers. Researchers estimate that about 1 in 4 patients with G/GEJ cancer who undergo surgery with curative intent develop recurrent disease within 1 year, highlighting a major area of unmet care. Given the high recurrence rates attributed to G/GEJ cancers, the authors speculated that adding durvalumab immunotherapy to standard care would improve outcomes and lessen recurrence.1-3

    Patients with G/GEJ cancer were randomly assigned to receive either 1500 mg of durvalumab or placebo every 4 weeks, plus FLOT for 4 cycles—2 cycles each of neoadjuvant and adjuvant therapy, respectively—followed by durvalumab or placebo every 4 weeks for 10 cycles. The primary end point was EFS, while key secondary end points included overall survival (OS) and pathological complete response (pCR), according to the authors.2

    In total, 474 patients each were randomly assigned to the durvalumab and placebo groups. The authors found that 2-year EFS was 67.4% among durvalumab-treated patients, whereas it was 58.5% in the placebo group (hazard ratio [HR] = 0.71 [95% CI, 0.58–0.86]; P < .001). Regarding OS rate, investigators measured an OS of 75.7% in the durvalumab group and 70.4% in the placebo group, while pCR was determined to be about 19.2% in the durvalumab-treated patients and 7.2% in the placebo patients.2

    Safety observations were consistent with the known tolerability profiles of both FLOT and durvalumab, with similar rates of grade 3 or higher adverse events between the 2 treatment arms.1,2

    Durvalumab Continues to Demonstrate Efficacy in Wide Range of Cancers

    As a human monoclonal antibody that can block the interaction of PD-L1, durvalumab is designed to counter a tumor’s immune-evading mechanisms while allowing for stronger immune responses against a cancer. Durvalumab is a standard-of-care option for a series of cancers and is approved for the treatment of unresectable non-small cell lung cancer, limited-stage small cell lung cancer, and muscle-invasive bladder cancer.1,4,5

    Pharmacists are pivotal in counseling patients on the use of durvalumab for the treatment of its approved indications. Given the myriad indications for durvalumab, it is understandable for a patient to feel overwhelmed or confused when considering whether durvalumab is the right choice for their treatment. Patients can be assured by their pharmacists as to the proven safety and efficacy of durvalumab, solidified in multiple extensive phase 3 trials.

    For patients with G/GEJ cancers, the granting of priority review and breakthrough designation by the FDA to durvalumab signifies the growing potential for the agent to transform the treatment paradigm for this population. Patients and pharmacists should remain aware and stay updated on durvalumab’s clinical development pipeline for this indication and be prepared if the agent eventually becomes approved for this treatment indication.

    REFERENCES
    1. AstraZeneca. IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers. News Release. Released July 28, 2025. Accessed July 28, 2025. https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-granted-priority-review-and-breakthrough-therapy-designation-in-the-US-for-patients-with-resectable-early-stage-gastric-and-gastroesophageal-junction-cancers.html?utm_source=external-comms&utm_medium=memo&utm_campaign=MATTERHORN+Priority+Review&utm_term=corporate&utm_content=matterhorn#!
    2. Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217-230. doi: 10.1056/NEJMoa2503701
    3. Li Y, Zhao H. Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles. Medicine (Baltimore). 2022;101(5):e28620. doi:10.1097/MD.0000000000028620
    4. McGovern G, Halpern L. Durvalumab receives FDA approval for muscle invasive bladder cancer. Pharmacy Times. Published March 28, 2025. Accessed July 28, 2025.
    5. McGovern G. FDA approves durvalumab for treatment of adult patients with LS-SCLC. Pharmacy Times. Published December 5, 2024. Accessed July 28, 2025. https://www.pharmacytimes.com/view/fda-approves-durvalumab-for-treatment-of-adults-patients-with-ls-sclc

    Continue Reading

  • Chinese Historical Film ‘Dead To Rights’ Starring Liu Haoran Gets North America, ANZ Release

    Chinese Historical Film ‘Dead To Rights’ Starring Liu Haoran Gets North America, ANZ Release

    Chinese historical drama Dead to Rights will get a North American release via Canada-based Niu Vision Media and U.S.-based Echelon Studios.

    Directed by Shen Ao (No More Bets), the film will open theatrically in the U.S. and Canada on August 15, ahead of a planned streaming rollout later this year.

    Dead to Rights has also secured theatrical releases via Niu Vision Media in Australia and New Zealand, where the film will arrive in theaters on August 7.

    Niu Vision Media said that the film has grossed 531M Chinese yuan (nearly $74M) so far, since the film’s July 25 release in China. The distributor estimated that Dead to Rights is headed toward a $450M box office run domestically.

    The film is set around the events of the Nanjing Massacre in 1937, where a postman named A Chang pretends to be a photo developer in a photo studio, developing photos for the Japanese army. He takes in a group of Chinese soldiers and civilians, turning the studio into a temporary shelter. However, in the face of the Japanese army’s cruel atrocities, A Chang risks his life to safely transfer the refugees and expose the evidence of the massacre to the public.

    The film stars Liu Haoran (Detective Chinatown, The Breaking Ice), Wang Chuanjun (Three-Body), Gao Ye (The Knockout), Daichi Harashima, Wang Xiao and Yang Enyou.

    Dead to Rights is a poignant, timely reminder of the human stories behind history’s darkest chapters,” said Niu Vision’s CEO, Fukun Wang. “We’re thrilled to partner once again with Echelon Studios to bring this extraordinary film to American audiences, both in theaters and later via streaming.”

    Sandro Gohoho, president of licensing and operations at Echelon Studios, added: “This is a story that demands to be seen. Dead to Rights exemplifies the kind of bold, meaningful storytelling we’re committed to supporting. We’re thrilled to help bring Shen Ao’s voice to digital audiences across the U.S.”

    Continue Reading

  • Clay paved Lorenzo Musetti's path, but hard road ahead is no fast lane to Turin – ATP Tour

    1. Clay paved Lorenzo Musetti’s path, but hard road ahead is no fast lane to Turin  ATP Tour
    2. Lorenzo Musetti states what he still really wants to do on the ATP Tour this season  Tennishead
    3. Lorenzo Musetti “Motivated” to Play His Best Tennis at the Canadian Open Following his Poor Grass-Court Form  MSN
    4. Lorenzo Musetti Discusses the Challenges of Having Too Much Variety in the Game  Yardbarker

    Continue Reading

  • Asteroid To Miss Earth, But It Might Hit The Moon

    Asteroid To Miss Earth, But It Might Hit The Moon

    View on Earth from Moon. Elements of this image furnished by NASA. 3D rendered illustration.

    Illustration showing a view of Earth from the moon.

    (Getty Images/NASA)

    Earth has dodged a celestial bullet, but the moon might not be so lucky, and that has scientists keeping their telescopes and minds trained on a massive asteroid called “2024 YR4.” That’s not its official name, but more on that later.

    When it was first discovered, this asteroid had a very small chance of impacting Earth in December of 2032, but later observations concluded the space rock no longer poses any significant risk to our planet.

    Since then, additional data has helped experts refine the asteroid’s potential trajectory and they say the probability of it striking the moon in 2032 has now risen to 4.3%. That’s still a very small chance, but there could be some complications for our planet if that collision happens.

    (MORE: Lego Man’s Epic Space Journey)

    Back To The Beginning

    2024 YR4 first caught astronomers’ attention in December 2024. It made headlines when its probability of impacting Earth got as high as 3%.

    It’s so far away that it appears as just a tiny glimmer, but using infrared images captured by NASA’s James Webb Space Telescope, scientists estimate that it’s the size of a 10-story building, about 200 feet in diameter.

    It’s considered a near-Earth asteroid, meaning it’s in an orbit that brings it within Earth’s region of the solar system.

    Its size earned the asteroid the nickname “city killer” since it could cause severe damage to a city or region if it struck Earth.

    2024 YR4 is the temporary name given to the rock. While those who discovered it will get to suggest an official name, it could be months or years before that official name is decided by the International Astronomical Union.

    What Happens If It Strikes The Moon?

    Illustration of an asteroid about to strike the moon, with a view of Earth.

    (Madie Homan)

    If this asteroid hits the moon, scientists say it will make impact at a speed of tens of thousands of miles per hour. That would create a huge crater, but more importantly, it could also send fragments of moon rock and granular lunar material flying off the moon.

    While it’s unlikely the Earth would face any significant danger from the lunar strike, that debris could put nearby astronauts at risk, as well as satellites that we depend on for GPS, cellphones, internet and weather forecasting.

    What about the International Space Station? Well that would be at risk, except that NASA plans to decommission and deorbit the ISS in 2031, a year before the asteroid’s potential impact.

    (MORE: New Images Show Universe Like Never Before)

    Would We Be Able To See The Collision?

    The latest calculations from June suggest it’s likely the asteroid could hit the near side of the moon, the side pointing towards us.

    So we could be able to see the once-in-a-lifetime collision here on Earth. Dr. Paul Wiegert, a physics and astronomy professor at Western University told Western News, “If YR4 hits the moon, it will be the largest asteroid to have hit the moon in about 5,000 years. It’s quite a rare event.”

    Wiegert says, “People at home will be able to see the explosion with small telescopes or even binoculars.”

    He also says that if moon rock is launched into space, “We should also get to see quite a spectacular meteor shower,” within a week of the collision.

    So What Now?

    Asteroid 2024 YR4 is currently too far away to detect with space or ground-based telescopes, as it orbits around the sun. But out of sight, does not mean out of mind – NASA expects to make more observations and collect new data when the asteroid’s orbit brings it back into Earth’s vicinity in 2028.

    Continue Reading

  • Pak teams will come for Asia Cup, Junior World Cup in India: HI | Hockey News

    Pak teams will come for Asia Cup, Junior World Cup in India: HI | Hockey News

    CHENNAI: After weeks of uncertainty surrounding their participation and mixed signals, it is now official that the Pakistan hockey team will take part in both major tournaments – the Asia Cup and the Junior Men’s Hockey World Cup — in India. The Asian meet is set to be held in Rajgir from August 27 to September 7, while the Junior World Cup will take place from November 28 to December 10 across two venues: Chennai and Madurai.Confirming the development, Hockey India (HI) treasurer and president of the Hockey Unit of Tamil Nadu, Sekar J Manoharan, told TOI that both the senior and junior teams from Pakistan have applied for visas.“Pakistan’s teams will definitely be coming. They’ve already submitted visa applications. The senior men’s team has applied with a contingent of 18 players and seven support staff,” Sekar said after the inauguration of the Sub-Junior Men’s National Hockey Championship here on Monday. Sekar also mentioned that the Indian junior team will arrive in Chennai in the first week of October for its preparatory camp.Earlier, there had been indications that the Pakistan Hockey Federation (PHF) might not send teams for the upcoming tournaments in India. It was speculated that the PHF had written to the FIH (International Hockey Federation) and the Asian Hockey Federation (AHF), expressing their reservations over sending the teams to India.HI President Dilip Tirkey said the federation has not received any official communication yet. “We too are hearing these talks, but we haven’t received any news from the Pakistan team officially yet. If we do receive it, we will take it up with FIH and they will decide how to go about it,” Tirkey told TOI.‘Selectors told to act if form dips’The India men’s team endured a poor campaign in the recent FIH Pro League, finishing eighth and suffering seven straight defeats. Reacting to the dismal performance, Tirkey said the federation is in talks with head coach Craig Fulton and the selectors.“The Pro League is very important for us. And now, we have more important tournaments coming up. If we see players who are not performing well and are unable to deliver, it’s on the selectors to take a call. And if there is a fall in form for some players who have been playing for a long time, we’ve told the selectors to watch out and take action.” Govt backing key to hosting big eventsAfter Chennai successfully hosted the Asian Champions Trophy in 2023, Tirkey said HI is confident of staging more marquee events here, thanks to strong support from the Tamil Nadu government.“TN govt supported us very much last time when we hosted ACT. And where there’s full support from the govt, we get the confidence to host international and domestic competitions. This is why we are hosting the Junior World Cup here. The Indian government knows how important security will be, so it will be given accordingly,” said Tirkey.


    Continue Reading

  • Brain’s blood vessels and immune cells play key role in Alzheimer’s and stroke

    Brain’s blood vessels and immune cells play key role in Alzheimer’s and stroke

    The brain’s health depends on more than just its neurons. A complex network of blood vessels and immune cells acts as the brain’s dedicated guardians-controlling what enters, cleaning up waste, and protecting it from threats by forming the blood-brain barrier.

    A new study from Gladstone Institutes and UC San Francisco (UCSF) reveals that many genetic risk factors for neurological diseases like Alzheimer’s and stroke exert their effects within these very guardian cells.

    When studying diseases affecting the brain, most research has focused on its resident neurons. I hope our findings lead to more interest in the cells forming the brain’s borders, which might actually take center stage in diseases like Alzheimer’s.”


    Andrew C. Yang, PhD, senior author of the new study, Gladstone Investigator 

    The findings, published in Neuron, address a long-standing question about where genetic risk begins and suggest that vulnerabilities in the brain’s defense system may be a key trigger for disease.

    Mapping the brain’s guardians

    For years, large-scale genetic studies have linked dozens of DNA variants to a higher risk of neurological diseases like Alzheimer’s, Parkinson’s, or multiple sclerosis.

    Yet, a major mystery has persisted: over 90% of these variants lie not in the genes themselves, but in the surrounding DNA that does not contain the code for making proteins, once dismissed as “junk DNA.” These regions act as complex dimmer switches, turning genes on or off.

    Until now, scientists haven’t had a full map of which switches control which genes or in which specific brain cells they operate, hindering the path from genetic discovery to new treatments.

    A new technology finds answers

    The blood-brain barrier is the brain’s frontline defense-a cellular border made up of blood vessel cells, immune cells, and other supporting cells that meticulously controls access to the brain.

    Yet, these important cells have been difficult to study, even using the field’s most powerful genetic techniques. To overcome this, the Gladstone team developed MultiVINE-seq, a technology that gently isolates the vascular and immune cells from postmortem human brain tissue.

    This technology allowed the team, for the first time, to simultaneously map two layers of information: the gene activity and the “dimmer switch” settings-known as chromatin accessibility-within each cell. The scientists studied 30 brain samples from individuals with and without neurological disease, giving them a detailed look at how genetic risk variants function across all major brain cell types.

    Working closely with Gladstone Investigators Ryan Corces, PhD, and Katie Pollard, PhD, lead authors Madigan Reid, PhD, and Shreya Menon integrated their single-cell atlas with large-scale genetic data from studies of Alzheimer’s, stroke, and other brain diseases. This revealed where disease-associated variants are active-and many were found to be active in vascular and immune cells rather than neurons.

    “Before this, we knew these genetic variants increased disease risk, but we didn’t know where or how they acted in the context of brain barrier cell types,” Reid says. “Our study shows that many of the variants are actually functioning in blood vessels and immune cells in the brain.”

    Different diseases, different disruptions

    One of the study’s most striking findings is that genetic risk variants affect the brain’s barrier system in fundamentally different ways, depending on the disease.

    “We were surprised to see that the genetic drivers for stroke and Alzheimer’s had such distinct effects, even though they both involve the brain’s blood vessels,” Reid says. “That tells us they involve really distinct mechanisms: structural weakening in stroke, and dysfunctional immune signaling in Alzheimer’s.”

    In stroke, genetic variants primarily affected genes responsible for the structural integrity of blood vessels, potentially weakening the vessels’ physical structure. Whereas in Alzheimer’s, the variants amplified genes that regulate immune activity, suggesting that overactive inflammation-not structural weakness-is the key issue.

    Among the Alzheimer’s-associated variants, one stood out. A common variant near the PTK2B gene, which is found in more than a third of the population, was most active in T cells, a type of immune cell. The variant enhances expression of the gene, which may promote T cell activation and entry into the brain, putting immune cells into overdrive. The team found these super-charged immune cells near amyloid plaques, the sticky protein buildups that mark Alzheimer’s.

    “Scientists are debating the role of T cells and related components of the immune system in Alzheimer’s,” Yang says. “Here, we provide genetic evidence in humans that a common Alzheimer’s risk factor may work through T cells.”

    Excitingly, PTK2B is a known “druggable” target, and therapies that inhibit its function are already in clinical trials for cancer. The new study opens a fresh avenue to investigate whether such drugs could be repurposed for Alzheimer’s disease.

    Location, location, location

    The study’s findings on the brain’s “guardian” cells point to two new opportunities for protecting the brain.

    Located at the critical interface between the brain and the body, the cells are continually influenced by lifestyle and environmental exposures, which could synergize with genetic predispositions to drive disease. Their location also makes them a promising target for future therapies, potentially allowing for drugs that can bolster the brain’s defenses from the “outside” without needing to cross the formidable blood-brain barrier.

    “This work brings the brain’s vascular and immune cells into the spotlight,” Yang says. “Given their unique location and role in establishing the brain’s relationship with the body and outside world, our work could inform new, more accessible drug targets and lifestyle interventions to protect the brain from the outside in.”

    Source:

    Journal reference:

    Reid, M. M., et al. (2025). Human brain vascular multi-omics elucidates disease-risk associations. Neuron. doi.org/10.1016/j.neuron.2025.07.001.

    Continue Reading

  • Backed by Philanthropy, CEVO Advancing Personalized Glaucoma Treatment with AI and Imaging | News

    Backed by Philanthropy, CEVO Advancing Personalized Glaucoma Treatment with AI and Imaging | News

    Current treatments come up short

    Glaucoma leads to damage to the optic nerve, which connects the eye to the brain and is essential for vision. This damage is most often linked to elevated pressure inside the eye, known as intraocular pressure. The eye constantly produces a clear fluid called aqueous humor, which flows through the front of the eye and drains out through a network of sophisticated, tiny channels. When these drainage pathways become blocked or don’t work properly, fluid builds up and pressure increases. Over time, this elevated pressure can harm the optic nerve and lead to vision loss. 

    “The root cause is believed to be the impaired outflow, and then the reduced flow causes the pressure,” Zhang said. “If we can find a way to address the flow challenges, we can prevent pressure from building up downstream. That’s the initial goal.” 

    Currently, the only proven non-surgical treatment to treat pressure buildup inside the eye is intraocular pressure reduction through medication. However, this form of treatment becomes less effective over time, and ultimately, many patients need surgery. One of the first-line surgical procedures is known as minimally invasive glaucoma surgery (MIGS), which safely and quickly lowers intraocular pressure by placing a stent in the eye along the flow pathway. While MIGS can be effective for many, its overall success has been limited.

    Zhang and colleagues believe this is due to a lack of personalized information about each patient’s eye structure and function, which prevents tailored surgical planning. These models may also inform decision making in second line surgical treatments that attempt to bypass some of the channels and possibly provide insight into additional targets for medical treatment.

    Using AI for personalized care

    CEVO’s high-resolution, AI-integrated imagery could bridge that gap and help create a 3D model of each patient’s eye. Instead of placing the stent in the easiest insertion area, a surgeon could view the digital twin and know exactly where to place the stent informed by a well-trained AI agent to predict the surgical outcome ahead of the actual surgery.

    This gift from the Forsythe Foundation and CEVO is perfectly timed to accelerate our discoveries which will undoubtedly lead to better treatment for our patients. Nicholas J. Volpe

    “AI is now driving all aspects of our lives,” Zhang said. “Engineering and AI have to be integrated.”

    Zhang is a professor of biomedical engineering at the McCormick School of Engineering. He codirects CEVO with Nicholas J. Volpe, the George W. and Edwina S. Tarry Professor of Ophthalmology and chair of the Department of Ophthalmology at the Northwestern University Feinberg School of Medicine.

    “One of Northwestern’s great strengths is the expertise it has in both engineering and ophthalmology,” Volpe said. “This gift from the Forsythe Foundation and CEVO is perfectly timed to accelerate our discoveries which will undoubtedly lead to better treatment for our patients.”

    Northwestern Engineering’s Cheng Sun, a professor of mechanical engineering, and Mark Johnson, a professor of biomedical engineering, are also contributing to the research.

    Continue Reading

  • Aboard the Legendary MV Agusta 750S Motorcycle

    Aboard the Legendary MV Agusta 750S Motorcycle

    MV Agusta is in the news again. Italy’s glamorous but often troubled motorcycle brand changed ownership in February amid financial problems, having recently launched an exotic superbike, the Superveloce 1000 Serie Oro, inspired by the machines ridden to Grand Prix glory by aces including John Surtees, Mike Hailwood and Giacomo Agostini.

    That’s situation normal for MV, whose history of race-developed superbikes and financial turmoil dates back to the early 1970s. Back then, the MV Agusta 750 Sport was among the fastest and most charismatic machines on the road, but could not prevent the decline that saw production abandoned before the end of the decade.

    MV’s glory days began in 1956, when Surtees won the 500cc world championship to trigger an unmatched era of domination by the small firm from Gallarate, north of Milan. By 1973, when this 750 Sport was built, Phil Read was about to win the factory’s 16th consecutive title in motorcycling’s premier class.

    The Sport, with its powerful double overhead camshaft, four-cylinder engine, high-end chassis parts and optional fairing, was closely related to the British star’s “works” four. But although MV had ruled racing for so long, the roadgoing replica was a recent development.

    During most of MV’s period of racing success the firm had not produced a multi-cylinder roadster. Instead, production had remained based on the small-capacity singles with which Count Domenico Agusta had entered the motorcycle business in 1945, when the Agusta aircraft company had been looking for a new direction at the end of World War II.

    Although a handsome 500cc four called the R19 Turismo had generated plenty of interest when displayed at the Milan Show as early as 1950, it had not been put into production. And when MV had belatedly introduced a roadgoing multi, the 600 Four of 1967 had been very different in style and spirit to the glamorous racers.

    MV Agusta MV750S side
    Roland Brown

    With high handlebars and a softy tuned, shaft-drive engine, the 600 Four produced just 52 brake horsepower and was barely capable of 100 mph. Worse still, its large, rectangular headlight and bulbous black fuel tank made for a peculiar-looking bike that had no chance of commercial success given its high price.

    Count Domenico had seemingly been more keen to maintain his factory team’s racetrack dominance than to produce a sports model that might encourage privateer rivals. But the 600’s failure was so complete—just 135 would be built in five years—that he finally relented.

    At the Milan Show in 1969, MV unveiled the model that many enthusiasts had long desired. The MV Agusta 750 Sport was beautiful, with a curvaceous gas tank, paintwork in red, white and blue; clip-on handlebars, rear-set footrests, a humped seat and a four-pipe exhaust system ending in slender chrome-plated megaphones.

    Its engine was heavily based on that of the 600, with bigger pistons that increased capacity to 743cc. A higher compression ratio, larger exhaust valves and the use of four instead of just two Dell’Orto carburetors lifted peak output to 65bhp at 7900 rpm.

    The roadster powerplant was very much a development of the competition unit, operating its twin overhead cams by a gear train between the inner cylinders. The race engine had no generator, so the roadster featured a combined starter/dynamo beneath the engine, connected by two belts. Crankcases were sandcast in aluminum rather than the race bikes’ magnesium.

    To widespread surprise, the Sport retained the 600’s shaft final drive, rather than using a lighter chain like the racers. Its frame design also followed the roadster’s, with a single top tube, rather than using twin tubes like the race bikes. Ceriani provided the 35mm front forks and twin rear shocks; Borrani the alloy wheel rims. A big, four-leading-shoe front brake from Grimeca, another Italian specialist firm, replaced the 600’s innovative but feeble pair of cable-operated discs.

    This bike is a 1973 Sport, restored using the uprated front end that was introduced late in that year, with twin 280mm front discs instead of the original drum. At the same time, the engine gained some internal updates and bigger 27mm carbs, increasing peak output to 69bhp and top speed to a genuine 120 mph.

    The bike also has the Brembo calipers that were supplied on later machines by the MV factory. Its fairing was available as a factory option (as were a half-fairing and bug screen). This Sport also has a pair of relatively modern Marzocchi remote-reservoir shocks in place of the same firm’s simpler and much-criticized originals.

    Riding it is a magical experience. You climb into the rather tall saddle and look out across the big, shapely fuel tank with its badge signifying MV’s record—and still unfinished, in 1973—number of 36 world championship wins. Ahead is a tall screen, below which sit a black-faced Smiths speedo and tachometer (earlier Sports were fitted with Veglia clocks) plus a simple pair of warning lights.

    Reach down to tickle some fuel into the Dell’Orto carbs at either side, then press the button in the cheap-looking switch box on the right clip-on handlebar. The starter unit puts its belt into motion, and the engine fires. Between the barks of the free-breathing pipes, you hear the rustling, grumbling mechanical sounds from inside the motor, which, like the racing units, has needle-roller and ball bearings throughout, instead of the more modern plain bearings.

    The robust four-cylinder unit’s relative weakness is its clutch, and this bike’s felt rather grabby as I hooked first gear with my right foot and pulled away. But once into its stride, the MV behaved flawlessly, surprising me by being docile and easy to ride at slow speed, idling happily and accelerating crisply when the ridged throttle was wound back, even with less than 2000 rpm on the tach.

    You can ride an MV Agusta four gently, but if there’s one bike in all the world that is wasted by doing so, it’s this one. The Sport didn’t match its manufacturer’s claim of a 129 mph top speed; magazine Cycle World managed only 114 mph. But very few bikes could approach its performance, and it was uniquely special to ride.

    For one thing, the Sport was superbly smooth, and encouraged hard riding with a slick gearbox that was a delight to use despite its unfamiliar right-foot, down-for-up change. Most memorable was the blend of induction and exhaust roar, as the tach needle flicked past 5000 rpm and the engine bellowed out a uniquely aggressive sound that transformed the most ordinary road into a Monza circuit straight.

    Thrilling engine performance I’d expected; what surprised me was that the handling was pretty darn good, too. The Sport’s frame wasn’t as rigid as the racers’, and the shaft drive assembly added 33 pounds, contributing to a substantial total of 507 pounds. But the shaft introduced very little torque reaction, and the shocks kept the rear end under control.

    High-speed stability was excellent, with the fairing doubtless playing its part by preventing unwanted forces from being transmitted through the clip-ons. Although the Sport felt tall and ungainly at slower speeds (and also when maneuvering it at a standstill, when the full fairing threatened to skin my thumbs on the tank), its steering was precise and reasonably light.

    Towards the end of the ride, I was sitting at some traffic lights, blipping the throttle and enjoying the cacophony of whirring gears and barking exhaust from this most deliciously noisy of bikes. The bike had no mirrors, so I didn’t realize there was another rider right behind me—until, as I accelerated away from the lights, he came past with throttle open and chin on the tank, clearly aiming to put this old machine in its place.

    With MV Agusta’s honor at stake, I wound back the Sport’s throttle and tucked down behind the tall screen. The feeling of raw, race-bred aggression was spine-tingling as the big four-cylinder engine reached 5500 rpm and kicked hard with a deafening bellow from its quartet of pipes.

    Moments later, I was travelling at… well, let’s just say fast, and treading down into top gear as the Sport closed the gap slightly. As we approached a sweeping right-hander I was right with him, in my imagination Hailwood on the TT circuit or Read at Spa-Francorchamps. The MV remained rock solid as I brushed its front brake lever, then dialed in the throttle again to keep the bike driving through.

    MV Agusta MV750S rider action
    Roland Brown

    Another short, loud burst of acceleration followed, and the gap was unchanged as we braked for the following roundabout, the twin front discs biting to slow the MV hard despite its narrow front tire. Then, as quickly as it had begun, the duel was over. The other rider turned off at the first exit while I carried on round, keen to return the bike on time and in one piece.

    It’s well to be slightly cautious when riding a MV Agusta 750 Sport, not least because this most exotic of motorcycles has always been among the most valuable. A 1973-model Sport reportedly sold at auction for £96,700 in 2018 ($129,926 in today’s dollars), so you’d need a six-figure sum for an example as clean and original as this one.

    Back in 1973, when Honda’s CB750 four cost £850 ($1142) and Kawasaki’s new 903cc Z1 was £1088 ($1462), the Sport’s price of £2300 ($3090) made it the most expensive bike on the market. Unfortunately for MV, the four-cylinder model’s intricate engine design, high construction cost, and low-volume production meant it still couldn’t be made profitably.

    MV Agusta MV750S side
    Roland Brown

    Despite that, MV continued to develop the four, in 1975 releasing the 750S America, built for the U.S. market with new, angular styling and a 789cc, 75bhp engine that pushed top speed towards 130 mph. Two years later, this was followed by the 850 Monza, with a more powerful 837cc engine. But by the end of 1978, the Agusta family had lost control of the MV motorcycle business, and production ended.

    It would be another two decades before MV Agusta’s rebirth in 1998 under new ownership, with the 750 F4 sportster. Since then, the firm has made headlines with spectacular models and financial struggles alike. Perhaps it will always be this way for this most glamorous but vulnerable of manufacturers.

    Meanwhile, the MV Agusta 750 Sport remains as a vivid reminder of the Italian marque’s glory days, which ended when Read won his second and MV’s 18th 500cc title in 1974. This is a classic superbike that has it all: looks, rarity, racing heritage, and a fiery performance and unique character that make it hugely thrilling to ride.

    Via Hagerty UK

    Continue Reading